Phentolamine mesylate injectable - Novalar/Septodont

Drug Profile

Phentolamine mesylate injectable - Novalar/Septodont

Alternative Names: NV-101; OraVerse; Phentolamine mesilate injectable - Novalar/Septodont

Latest Information Update: 11 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novalar Pharmaceuticals
  • Developer Novalar Pharmaceuticals; Sanofi; Septodont
  • Class Erectile dysfunction therapies; Imidazoles; Peripheral vasodilators; Small molecules
  • Mechanism of Action Alpha adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anaesthesia

Most Recent Events

  • 11 May 2017 No recent reports on development identified - Registered for Anaesthesia in France and United Kingdom (Submucosal)
  • 18 Mar 2011 Septodont acquires injectable phentolamine mesylate from Novalar for North America and unpartnered international markets
  • 14 Jul 2010 Preregistration for Anaesthesia in Spain, France, Italy, Germany, and United Kingdom (Submucosal) through decentralised procedure
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top